Ozempic sells twice as fast as Victoza and Trulicity
After one and a half year on the market, Novo Nordisk's GLP-1-analogue Ozempic generates twice as much revenue as Victoza and Trulicity did in the same period after their launch. Novo Nordisk is "very satisfied" with the results.
Novo Nordisk's growth driver Ozempic has had an extremely good start on the diabetes market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo Nordisk prepares for label expansion of prize asset
For abonnenter
